Hyperpituitarism: Clinical Trials

297 trials for Hyperpituitarism, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

175 completed, 45 unknown, 25 recruiting, 25 terminated. 50 Phase 3, 45 Phase 2, 34 Phase 4, 31 Not applicable, 18 Phase 1.

By phase and status

Phase	Trials	Status
Phase 3	50	Completed 36, Terminated 6, Recruiting 3, Unknown 3, Not yet recruiting 1, Withdrawn 1
Phase 2	45	Completed 28, Terminated 6, Unknown 5, Active not recruiting 2, Recruiting 2, Withdrawn 2
Phase 4	34	Completed 23, Unknown 5, Terminated 4, Enrolling by invitation 1, Recruiting 1
Not applicable	31	Completed 18, Unknown 7, Recruiting 2, Active not recruiting 1, Enrolling by invitation 1, Suspended 1, Terminated 1
Phase 1	18	Completed 11, Recruiting 2, Terminated 2, Active not recruiting 1, Suspended 1, Unknown 1
Early Phase 1	2	Completed 1, Recruiting 1

Follow Hyperpituitarism: new trials by email Literature Review of Hyperpituitarism trials Research Report on Hyperpituitarism

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Hypoproteic Diet in Acromegaly Usual clinical practice + hypoproteic diet - Acromegaly	Not applicable	Suspended	Azienda Ospedaliero Universitaria Maggiore della Carita	12	2026-12-01	2026-10-29
PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT) - Acromegaly Due to Pituitary Adenoma, Cushing's Disease	Phase 3	Not yet recruiting	University College, London	82	2026-09-01	2026-10-01
A Study to Evaluate MAR002 for Acromegaly MAR002, Placebo - Acromegaly	Phase 2	Recruiting	Marea Therapeutics	72	2026-07-23	2026-09-11
Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal Disorders Outpatient Clinic of the Clinical Unit of Endocrinology at the Modena University Hospital (AOU Modena) Cushing s Syndrome, Cushing Disease		Recruiting	Azienda Ospedaliero-Universitaria di Modena	2000	2026-07-09	2026-11-09
Direct Versus Video Laryngoscopy in Patients With Acromegaly Acromegaly, Nonfunctioning Pituitary Adenoma		Not yet recruiting	Muzaffer GENCER	40	2026-07-01	2026-06-22
A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25) T25-Fast, Mycapssa, T25-Fed - Acromegaly	Phase 1	Completed	Triastek (Shanghai) Limited	18	2026-06-25	2026-09-16
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly Octreotide subcutaneous depot - Acromegaly		Recruiting	Camurus AB	200	2026-06-05	2026-10-27
Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease [18F]FET PET-MRI - Cushing Disease	Not applicable	Enrolling by invitation	University Hospital, Basel, Switzerland	43	2026-06-04	2026-07-06
Combination Osilodrostat and Cabergoline in Cushing's Disease osilodrostat, osilodrostat and cabergoline - Cushing Disease Due to Increased ACTH Secretion	Phase 4	Enrolling by invitation	University of Basrah	50	2026-05-11	2026-05-22
FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET - Cushing Disease, Pituitary Adenoma	Early Phase 1	Recruiting	Mayo Clinic	50	2026-04-27	2026-10-30
A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteers NTQ6179, NTQ6179 placebo - Acromegaly	Phase 1	Recruiting	Nanjing Chia-tai Tianqing Pharmaceutical	56	2026-04-23	2026-11-03
DDAVP for Pituitary Adenoma Desmopressin acetate - Cushing's Disease, Pituitary Adenoma	Not applicable	Recruiting	National Institute of Neurological Disorders and Stroke (NINDS)	22	2026-03-09	2026-04-09
Safety and Potency of a High Cabergoline Dosage in Microprolactinomas Cabergoline - Prolactinoma, Prolactin Excess	Phase 3	Recruiting	University of Sao Paulo General Hospital	70	2026-03-04	2026-03-13
Ultrasound in Predicting Difficult Intubation in Acromegaly Patients observational study - Acromegaly Due to Pituitary Adenoma, Difficult Intubation		Not yet recruiting	Başakşehir Çam & Sakura City Hospital	34	2025-12-25	2025-12-29
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs Debio 4126, Placebo - Acromegaly	Phase 3	Recruiting	Debiopharm International SA	119	2025-11-26	2026-10-23
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly ALXN2420, Placebo - Acromegaly	Phase 2	Terminated	Alexion Pharmaceuticals, Inc.	8	2025-10-28	2026-08-07
Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment Cabergoline (Dopamine Agonist) - Prolactinoma	Phase 4	Recruiting	University Hospital, Basel, Switzerland	60	2025-09-16	2025-09-23
A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets Cabergoline tablets, Bromocriptine mesylate tablets - Hyperprolactinemia	Phase 3	Recruiting	Changchun GeneScience Pharmaceutical Co., Ltd.	382	2025-09-12	2025-10-02
Effects of Pasireotide Lar Therapy on Bone Metabolism morphometric spine radiography - Acromegaly Due to Pituitary Adenoma, Acromegaly		Recruiting	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	120	2025-09-08	2025-09-18
Study of MAR002 in Healthy Men MAR002, Placebo - Acromegaly	Phase 1	Recruiting	Marea Therapeutics	45	2025-08-11	2026-01-12

Hyperpituitarism: Clinical Trials

297 trials for Hyperpituitarism, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

By phase and status

Trials newest first · largest first

Narrower conditions

Broader conditions

Interventions

Sponsors

Countries

Top investigators

Results publications

NIH funding